International Society on Thrombosis and Haemostasis - 34th Congress, 2026 (ISTH) 11 - 15 July 2026

Concizumab prophylaxis in paediatric participants with haemophilia A/B with inhibitors in the phase 3 explorer10 study: Efficacy, safety and PK/PD results from the 32-week cut-off

Authors :

Sonata Šaulytė Trakymienė¹, Rukhmi Bhat², Anthony KC Chan³, Anastasios Giakoumis⁴, Victor Jiménez Yuste⁵, Kaan Kavakli⁶, Maria Knudsen⁴, Johnny Mahlangu⁷, Mary Mathias⁸, Chiai Nagae⁹, Salim Mohamed Nekkal¹⁰, Nita Radhakrishnan¹¹, Allison P Wheeler¹² and Giancarlo Castaman¹³

Affiliations

View Details Hide Details

Download poster (.pdf)

Keywords

Rare Blood Disorders

Congress oral presentation

Concizumab

Search Science Hub

Are you a healthcare professional?

Concizumab prophylaxis in paediatric participants with haemophilia A/B with inhibitors in the phase 3 explorer10 study: Efficacy, safety and PK/PD results from the 32-week cut-off